Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaemoneticsFRA:HAZ 84 EV-to-FCF is 17.65 as of Aug. 15, 2026, which is 62% below its 10-year median of 45.95. GuruFocus rates FRA:HAZ with a GF Score™ of 84/100 and a GF Value™ of €73.15 (Fairly Valued). The stock has 5 warning signs investors should review. Among 409 Medical Devices & Instruments companies, Haemonetics ranks better than 66.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Haemonetics's Enterprise Value is €4,406 Mil.
Haemonetics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €250 Mil. Therefore, Haemonetics's EV-to-FCF for today is 17.65.
The historical rank and industry rank for Haemonetics's EV-to-FCF or its related term are showing as below:
FRA:HAZ'
s EV-to-FCF Range Over the Past 10 Years
Min: 11.04 Med: 45.95 Max: 187.03
Current: 17.45
During the past 13 years, the highest EV-to-FCF of Haemonetics was 187.03. The lowest was 11.04. And the median was 45.95.
FRA:HAZ's EV-to-FCF is ranked better than 66.5% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.41
vs FRA:HAZ: 17.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haemonetics's PE Ratio (TTM) for today is calculated as:
Haemonetics's share price for today is €78.00.
Haemonetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.745.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Haemonetics EV-to-FCF Related Terms
Haemonetics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Haemonetics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Haemonetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Haemonetics's EV-to-FCF falls into.
Haemonetics's current Enterprise Value is €4,406 Mil.
Haemonetics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €250 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (FRA:HAZ) has a EV-to-FCF of 17.65 as of Aug. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haemonetics and its competitors. This is 62% below median its historical median of 45.95. Over the past decade, Haemonetics' EV-to-FCF has ranged from 11.04 to 187.03. According to the industry distribution chart, Haemonetics ranks #137 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is Haemonetics' EV-to-FCF too high?
Haemonetics' current EV-to-FCF of 17.65 is 62% below median its 10-year median of 45.95. Over the past 10 years, this metric has ranged from a low of 11.04 to a high of 187.03. The Medical Devices & Instruments industry median EV-to-FCF is 24.41. Haemonetics' value of 17.65 is 27.7% below this industry median. Based on the distribution chart, Haemonetics ranks #137 out of 409 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Haemonetics has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' EV-to-FCF compare to IRTC and ITGR?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #137 out of 409 companies for EV-to-FCF. This puts Haemonetics in the upper half of its industry. The industry median EV-to-FCF is 24.41. Haemonetics' value of 17.65 is 27.7% below this benchmark. Historically, Haemonetics' own EV-to-FCF has ranged from 11.04 to 187.03 over the past decade. While the company's 10-year median is 45.95 vs. the industry median of 24.41, Haemonetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.41, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current EV-to-FCF of 17.65 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current EV-to-FCF is 17.65, which is 62% below median its own 10-year median of 45.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (FRA:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €73.15, compared to a current price of €78.00 — trading 6.6% above its estimated fair value. The current EV-to-FCF is 17.65, which is 62% below median its 10-year median of 45.95 and 27.7% below the Medical Devices & Instruments industry median of 24.41. Haemonetics' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Haemonetics (FRA:HAZ), the current EV-to-FCF is 17.65 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (FRA:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued.
The current stock price of €78.00 is trading 6.6% above its estimated GF Value™ of €73.15.
GuruFocus considers Haemonetics to be Fairly Valued.
Key valuation signals for FRA:HAZ:
EV-to-FCF: 17.65 (62% below median its 10-year median of 45.95)
GF Value™: €73.15 vs. price of €78.00 (6.6% above fair value)
Industry Position: 27.7% below the Medical Devices & Instruments median (#137 of 409)
No single metric tells the full story. See the FRA:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
84GF Score
Get the complete analysis for FRA:HAZ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HAZ has been successfully added to your 
